Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

2(50%)

Results Posted

150%(3 trials)

Phase Distribution

Ph phase_3

50%

Ph phase_4

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 3Large-scale testing

2(66.7%)

Phase 4Post-market surveillance

1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(2)

Detailed Status

Completed2

Recruiting1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 32 (66.7%)

Phase 41 (33.3%)

Trials by Status

recruiting125%

completed250%

active_not_recruiting125%

Recent Activity

2 active trials

Showing 4 of 4

active_not_recruitingphase_3

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

NCT03299049

completedphase_4

SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension

NCT05549726

recruiting

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

NCT06405464

completedphase_3

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

NCT05896761

Clinical Trials (4)

Showing 4 of 4 trials

NCT03299049Phase 3

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

Active Not Recruiting

NCT05549726Phase 4

SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension

Completed

NCT06405464

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

Recruiting

NCT05896761Phase 3

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4